Hydreight Technologies (NURS) Investor Update summary

Strategic rationale and market context

• The acquisition of a stake in Perfect Scripts aligns with a vision to vertically integrate pharmacy operations, enhancing control over supply chain and risk management across three healthcare verticals.

• Compounding pharmacies are gaining value due to drug shortages, telemedicine growth, and demand for personalized medicine, with the market projected to grow from CAD 6.3B in 2024 to CAD 10.7B by 2033.

• The partnership provides access to a 503A pharmacy licensed in all 50 states, enabling direct-to-consumer and B2B2C healthcare delivery at scale.

• Integration with proprietary technology and POS solutions aims to streamline operations for brick-and-mortar and virtual care platforms.

Deal structure and execution

• Initial acquisition is for 5% of Perfect Scripts, with an option to increase ownership up to 40% via cash or stock, subject to third-party validation and annual caps.

• The transaction is structured with share restrictions and a 45-day closing window, with due diligence covering technical, legal, and financial aspects.

• Restructuring consolidates all Perfect Scripts entities under one parent, facilitating partial ownership and operational alignment.

• The 503B pharmacy initiative is underway, targeting production readiness by Q1/Q2 next year, further expanding supply chain control.

Operational and financial impact

• Order volumes are ramping up, with June targets met (7,000–10,000 orders) and July expected to reach 35,000–70,000 orders, trending toward 2,000+ daily orders.

• Margins have improved from low teens to high teens, with a goal to reach 20–30% as integration deepens and order volumes scale.

• The partnership is expected to drive higher profitability, competitive moat expansion, and operational scalability, with further updates on performance and integration forthcoming.

• The company maintains strong cash flow and does not anticipate needing external capital for the 503B investment at this stage.